These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 30735438)
1. Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome. Werner M; Jordan PM; Romp E; Czapka A; Rao Z; Kretzer C; Koeberle A; Garscha U; Pace S; Claesson HE; Serhan CN; Werz O; Gerstmeier J FASEB J; 2019 May; 33(5):6140-6153. PubMed ID: 30735438 [TBL] [Abstract][Full Text] [Related]
2. Natural chalcones elicit formation of specialized pro-resolving mediators and related 15-lipoxygenase products in human macrophages. Kretzer C; Jordan PM; Meyer KPL; Hoff D; Werner M; Hofstetter RK; Koeberle A; Cala Peralta A; Viault G; Seraphin D; Richomme P; Helesbeux JJ; Stuppner H; Temml V; Schuster D; Werz O Biochem Pharmacol; 2022 Jan; 195():114825. PubMed ID: 34762841 [TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory celastrol promotes a switch from leukotriene biosynthesis to formation of specialized pro-resolving lipid mediators. Pace S; Zhang K; Jordan PM; Bilancia R; Wang W; Börner F; Hofstetter RK; Potenza M; Kretzer C; Gerstmeier J; Fischer D; Lorkowski S; Gilbert NC; Newcomer ME; Rossi A; Chen X; Werz O Pharmacol Res; 2021 May; 167():105556. PubMed ID: 33812006 [TBL] [Abstract][Full Text] [Related]
4. Beneficial Modulation of Lipid Mediator Biosynthesis in Innate Immune Cells by Antirheumatic Zhang K; Pace S; Jordan PM; Peltner LK; Weber A; Fischer D; Hofstetter RK; Chen X; Werz O Biomolecules; 2021 May; 11(5):. PubMed ID: 34067705 [No Abstract] [Full Text] [Related]
5. Dual acting anti-inflammatory drugs: a reappraisal. Bertolini A; Ottani A; Sandrini M Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348 [TBL] [Abstract][Full Text] [Related]
6. Differential impact of 5-lipoxygenase-activating protein antagonists on the biosynthesis of leukotrienes and of specialized pro-resolving mediators. Dahlke P; Peltner LK; Jordan PM; Werz O Front Pharmacol; 2023; 14():1219160. PubMed ID: 37680719 [TBL] [Abstract][Full Text] [Related]
9. Macrophage Proresolving Mediators-the When and Where. Dalli J; Serhan C Microbiol Spectr; 2016 Jun; 4(3):. PubMed ID: 27337457 [TBL] [Abstract][Full Text] [Related]
10. Dual acting anti-inflammatory drugs. Leone S; Ottani A; Bertolini A Curr Top Med Chem; 2007; 7(3):265-75. PubMed ID: 17305569 [TBL] [Abstract][Full Text] [Related]
11. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Celotti F; Durand T Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558 [TBL] [Abstract][Full Text] [Related]
12. Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201. Kretzer C; Jordan PM; Bilancia R; Rossi A; Gür Maz T; Banoglu E; Schubert US; Werz O J Inflamm Res; 2022; 15():911-925. PubMed ID: 35173459 [TBL] [Abstract][Full Text] [Related]
13. Prostaglandins and leukotrienes: advances in eicosanoid biology. Funk CD Science; 2001 Nov; 294(5548):1871-5. PubMed ID: 11729303 [TBL] [Abstract][Full Text] [Related]
14. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Bertolini A; Ottani A; Sandrini M Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982 [TBL] [Abstract][Full Text] [Related]
15. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Fiorucci S; Meli R; Bucci M; Cirino G Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379 [TBL] [Abstract][Full Text] [Related]
16. GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures. Lukic A; Larssen P; Fauland A; Samuelsson B; Wheelock CE; Gabrielsson S; Radmark O FASEB J; 2017 Oct; 31(10):4370-4381. PubMed ID: 28637652 [TBL] [Abstract][Full Text] [Related]
17. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Werz O; Gerstmeier J; Libreros S; De la Rosa X; Werner M; Norris PC; Chiang N; Serhan CN Nat Commun; 2018 Jan; 9(1):59. PubMed ID: 29302056 [TBL] [Abstract][Full Text] [Related]
18. Rotational constriction of curcuminoids impacts 5-lipoxygenase and mPGES-1 inhibition and evokes a lipid mediator class switch in macrophages. Rao Z; Caprioglio D; Gollowitzer A; Kretzer C; Imperio D; Collado JA; Waltl L; Lackner S; Appendino G; Muñoz E; Temml V; Werz O; Minassi A; Koeberle A Biochem Pharmacol; 2022 Sep; 203():115202. PubMed ID: 35932797 [TBL] [Abstract][Full Text] [Related]
19. Formation of eicosanoids and other oxylipins in human macrophages. Radmark O Biochem Pharmacol; 2022 Oct; 204():115210. PubMed ID: 35973581 [TBL] [Abstract][Full Text] [Related]
20. The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation. Kong W; Hooper KM; Ganea D Brain Behav Immun; 2016 Mar; 53():59-71. PubMed ID: 26541818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]